Against this backdrop, the concept of a “vitamin D–responsive endotype” of AD has emerged—referring to a subset of patients in whom clinical response to supplementation is modulated by immunological phenotype, genetic background, degree of deficiency, and local VDR activity. The gene discussed is VDR; the disease is Alzheimer disease.